Skip to main content

Table 1 Baseline Characteristics

From: Going beyond the mean: economic benefits of myocardial infarction secondary prevention

  All not pre-exposed to prophylactic drugs pre-exposed to prophylactic drugs
N 1840 (100%) 542 (100%) 1298 (100%)
Demographics
 Median age [interquartile range] 73.0 [61.5; 82.0] 61.0 [53.0; 73.0] 76.0 [67.0; 84.0]
 Female sex 654 (35.5%) 157 (29.0%) 497 (38.3%)
 Living in French/Italian speaking cantons (vs. Swiss German) 466 (25.3%) 136 (25.1%) 330 (25.4%)
 Living in urban region (vs. rural/suburban) 1391 (75.6%) 413 (76.2%) 978 (75.3%)
Insurance Characteristics
 Annual deductible > 500 Swiss Francs 240 (13.0%) 147 (27.1%) 93 (7.2%)
 Having supplementary insurance 1408 (76.5%) 398 (73.4%) 1010 (77.8%)
 Having a managed care contract 741 (40.3%) 253 (46.7%) 488 (37.6%)
Prior medication use for chronic co-morbidities
 Cancer 33 (1.8%) 7 (1.3%) 26 (2.0%)
 Cardiovascular diseases 1361 (74.0%) 63 (11.6%) 1298 (100.0%)
 Type 1 or type 2 diabetes 382 (20.8%) 39 (7.2%) 343 (26.4%)
 Hypertension 709 (38.5%) 48 (8.9%) 661 (50.9%)
 Median number of chronic comorbidities [interquartile range] 3.0 [2.0; 3.0] 3.0 [2.0; 3.0] 3.0 [3.0; 3.0]
High-intensity statin use prior index date 694 (37.7%) 45 (8.3%) 649 (50.0%)
Inpatient stays prior to index date 428 (23.3%) 50 (9.2%) 378 (29.1%)
High outpatient medication costs prior to index date 154 (8.4%) 24 (4.4%) 130 (10.0%)
Treatments received within 30 days after index date
 Aspirin 1212 (65.9%) 455 (83.9%) 757 (58.3%)
 P2Y12 inhibitors 1191 (64.7%) 406 (74.9%) 785 (60.5%)
 ACE/ARB 1144 (62.2%) 366 (67.5%) 778 (59.9%)
 Betablocker 1117 (60.7%) 358 (66.1%) 759 (58.5%)
 High-intensity statins 990 (53.8%) 386 (71.2%) 604 (46.5%)
Combination treatments received
 Three drug classesa 486 (26.4%) 161 (29.7%) 325 (25.0%)
 Four drug classesa 595 (32.3%) 236 (43.5%) 359 (27.7%)
Clinical outcomes 390 days after index date (30 day assessment period and 360 day outcome observation period)
 Having died after index date 175 (9.5%) 24 (4.4%) 151 (11.6%)
 Having had inpatient hospital stays after index date 735 (39.9%) 146 (26.9%) 589 (45.4%)
  1. a Four class treatments include high intensity statins, beta-blockers, ACE/ARB and either Aspirin or P2Y12 inhibitors. Three class treatments only include three of the four drug classes